Remove Engineering Remove Immune Response Remove Packaging
article thumbnail

A Visual Guide to Gene Delivery

Codon

For the former, clinicians extract a patient’s cells, engineer them in a laboratory, and then infuse them back into the body. And even if all these economic hurdles are overcome, there are still three main technical challenges to solve: cargo capacity, specificity, and immune response.

article thumbnail

Case study: gget’s new Open Target module

The Open Targets Blog

gget ( [link] ) is a free, open-source command-line tool and Python package designed to enable efficient querying of large genomic databases, such as Ensembl, UniProt, and NCBI. We chatted to the team about the module, and how it facilitates access to Open Targets Platform data. What is gget?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Visual Guide to Genome Editors

Codon

The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. pyogenes protein — whose compactness makes them far easier to package into viral vectors and deliver into the human body. Collectively, these repeat-protospacer regions are known as CRISPR arrays.

DNA
article thumbnail

Unveiling neoantigen-directed cancer treatment

Drug Target Review

As part of the TCR discovery process and preclinical data package, Adaptive performs rigorous functional characterisation and safety assessments of potent, therapeutic grade antigen-specific TCRs. Genentech is responsible for engineering adaptive-discovered TCRs into T cells and manufacturing the T cell therapy product candidate.

article thumbnail

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. It is packaged in a ready-to-use liquid formulation in 10-dose vials. BARDA is providing up to $1.75 billion under a Department of Defense agreement. About NVX-CoV2373.

article thumbnail

New insights into the role of viral capsids in gene therapy safety

Drug Target Review

2,3 Engineering both the capsid and DNA cargo improves the safety and efficacy of rAAV vectors and expands their clinical applications. Therefore, vectors based on these serotypes may enable targeted gene delivery and optimal transduction efficiency.

article thumbnail

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

The Pharma Data

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.